copy and paste this google map to your website or blog!
Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples: WordPress Example, Blogger Example)
Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer
(Any information to deal,buy, sell, quote for products or service)
Novartis | Cafepharma Novartis (NVS) has received FDA approval for Itvisma, a groundbreaking gene therapy for spinal muscular atrophy (SMA) Itvisma is the first therapy targeting the genetic basis of SMA with a single, fixed dose
Avidity Biosciences | Cafepharma Shares of Novartis fell 1% on Monday following news of the company's plans to acquire U S biotech Avidity Biosciences for about $12 billion, marking the Swiss drugmaker's largest acquisition under CEO Vas Narasimhan
Pluvicto | Cafepharma Novartis’ radiopharmaceutical Pluvicto (lutetium Lu 177 vipivotide tetraxetan) met its primary endpoint in the Phase III PSMAfore trial, resulting in better radiographic progression-free survival in PSMA-positive patients with metastatic castration-resistant prostate cancer, the company announced Monday
Xolair | Cafepharma Xolair, a 20-year-old asthma drug sold by Roche (ROG S) and Novartis (NOVN S) significantly reduced allergic reactions in people with multiple severe food allergies in a late-stage trial, researchers reported on Sunday at a medical meeting
radioligands | Cafepharma Novartis has shared detailed data showing its radioligand therapy Pluvicto could slow the progression of certain hormone-sensitive prostate cancers ahead of a planned application with the FDA
October 27 2025 - Novartis shares slip, Avidity soars after $12 billion . . . Novartis shares slip, Avidity soars after $12 billion biotech dealNovartis boardInnovent, Lilly's mazdutide trumps Novo's semaglutide in head-to-head diabetes, weight loss studyEli Lilly board, Novo Nordisk boardMapLight goes public via $250M IPO to fund Cobenfy competitor
Cafepharma News Latest news and updates on pharmaceutical and medical sales, including breakthrough treatments and industry trends
‘Not prudent’ for Novartis to join GLP-1 obesity race as late-runner . . . The breakout success of GLP-1 drugs by Novo Nordisk and Eli Lilly has persuaded many of their Big Pharma peers to enter their own newly acquired candidates into the obesity race But don’t expect Novartis to be joining them anytime soon “Coming in late with another one of the oral or injectable GLP [or] GIPs, we think is not a prudent approach for us as a company,” Novartis CEO Vas